ABSTRACT
INTRODUCTION
Acute kidney injury (AKI) is a common inpatient and outpatient condition and associated with myriad morbidity, including a substantially increased risk of development and progression of chronic kidney disease (CKD) as well as end-stage renal disease (ESRD). [1] [2] [3] [4] Despite increasing recognition of AKI as a serious public health concern, few effective therapies are available. One reason for the lack of therapies is the controversy over whether AKI itself causes an irreversible loss of kidney function. 5, 6 The current consensus guidelines define AKI by an increase in serum creatinine from baseline of 0.3 mg/dL within 48 hours or 50% within 7 days, without requirement that the decreased kidney function be sustained. 7 People who develop AKI tend to be older with a higher burden of comorbidities, including reduced estimated glomerular filtration rate (eGFR) and elevated albuminuria. 8, 9 Some have argued that the adverse outcomes after mild AKI may simply be a result of the underlying phenotype and not related to AKI. 6, 10 As such, AKI is not currently accepted by the US Food and Drug Association (FDA) as an endpoint for registration trials.
A better understanding of the risk for ESRD after AKI could inform the design and execution of Phase 3 clinical trials and facilitate drug development. In clinical trials of CKD progression, a 30% decline in eGFR has been suggested as an alternative surrogate endpoint for ESRD, which may enable better-powered trials with a smaller sample size than the traditionally accepted surrogate endpoint of doubling of serum creatinine. 11,12 13 A comparable surrogate outcome following AKI might do the same; indeed, the FDA has accepted an irreversible loss of kidney function following AKI as an endpoint in some studies. However, there are little data to support what magnitude of eGFR decline after a transient loss in kidney function is meaningful and when the endpoint should be assessed (i.e., when the change likely constitutes an irreversible loss).
The objective of this study was to quantify the continuous association between the decrement in eGFR at various time-points post-AKI and subsequent ESRD, thus providing evidence to support a potential surrogate endpoint in trials of AKI prevention or treatment. We focused on AKI occurring after major surgery, since postoperative AKI is one of the most common settings for trials of AKI prevention. Because mortality is an important and competing endpoint to ESRD after AKI, we also evaluated the association of post-AKI eGFR decline with mortality.
RESULTS

Baseline characteristics
The 161,185 US veterans comprising the study population were majority male (96.3%), 16.9% African American, and had an average age of 64 years ( Table 1) . Mean pre-hospitalization eGFR was 80 ml/min/1.73 m 2 , and 12% of the population had eGFR <60 ml/min/1.73 m 2 . Mean number of creatinine levels in the year prior to surgery was 3.5 (standard deviation, 2.7). The most common type of surgery was general (28%), followed by orthopedic (21%), vascular (16%), and cardiac (14%) 
Survival to post-discharge time points and frequency of eGFR assessment.
Survival to post-discharge time points differed by post-operative AKI status ( Table 2) . At 30-, 60-, and 90-days post-hospital discharge, 98%, 97%, and 96% of those without post-operative AKI were alive; as were 89%, 88%, and 87% of the patients with post-operative AKI. At 1-year, comparable estimates were 92% and 81% of the patients without and with post-operative AKI.
The frequency of creatinine checks among survivors also differed by post-AKI status: at 30-days (+/-15 days), 41% of people without post-operative AKI and 54% of those with post-operative AKI had a creatinine assessment; at 60-days (+/-30 days), 53% and 63% had a creatinine assessment; at 90-days (+/-30 days), 49%
and 57% had a creatinine assessment; and at 1-year (+/-3 months), 78% and 82% had a creatinine assessment.
Average number of eGFR assessments during each time window was greater among those who had experienced post-operative AKI, and ranged from 2.7 and 3.9 at 30-days +/-15 days post discharge to 3.4 and 4.5 at 1 year +/-3 months among persons without and with post-operative AKI, respectively. Persons who did not have creatinine checks tended to be younger, more often female, more often African American with few comorbid conditions ( Table S1 ). Persons without measurements of creatinine also had a lower proportion of subsequent ESRD and death, as did participants without AKI (Table S2) .
Frequency of eGFR decline post-discharge, by AKI stage
Higher AKI stage was associated with greater likelihood of eGFR decline, although this association was attenuated in later time periods. For example, the frequency of a 30% decline at 30-days was 3%, 12%, 21%, and 39% for no AKI, AKI Stage 1, AKI Stage 2, and AKI Stage 3; at 60-days, the frequency was 2%, 10%, 17%, and 29%; at 90-days, the frequency was 3%, 10%, 16%, and 26%; and at 1-year, the frequency was 3%, 12%, 15%, and 25%. In adjusted analyses, the odds of a 30% eGFR decline at 30-days were 4.06 (95% CI: 11.25). Among those with measures of creatinine, most people with an eGFR decline >30% at 90 days also had an eGFR decline >30% at 60 days and 30 days (79% and 60%, respectively).
Risk of ESRD after post-discharge decline in eGFR
There were 787 cases of ESRD and 43,668 deaths over a median follow-up of 3.8 years after hospital discharge, with greater risk in those with AKI and 30% decline compared to those without AKI or without 30% decline ( Figure S1 ). There was a graded relationship between post-discharge eGFR decline and subsequent ESRD risk among patients with and without post-operative AKI (Figure 1) . Risks of ESRD exceeded 5-fold at an eGFR decline of 30% for all time-points post-discharge and were higher with greater magnitude of decline (Table 3) . at 90-days, and 7.3-fold (95% CI: 5.3-10.0) at 1-year. The likelihood ratio of eGFR decline of 30% at 30-days was 5.78, with lower sensitivity but higher specificity (Figure 2 ; Table 4 ).
Risk of death after post-discharge decline in eGFR
The risk of death associated with eGFR decline after post-operative AKI was smaller than that of ESRD and fairly consistent over the various time windows (Table S3) There was no consistent difference in risk of death by AKI stage after eGFR decline was accounted for, and persons experiencing eGFR decline without AKI also had a higher risk of mortality: 1.3-fold (95% CI: 1.3-1.4) at 30-days, 1.5-fold (95% CI: 1.4-1.6) at 60-days, 1.5-fold (95% CI: 1.4-1.6) at 90-days, and 1.4-fold (95% CI:
1.4-1.5) at 1-year ( Figure S2 ).
Sensitivity analysis
In sensitivity analyses requiring that a patient have at least two creatinine measurements during the postdischarge window to confirm eGFR decline, results were similar ( Figure S3 ). Similarly, results from analyses excluding ear-nose-throat surgery, accounting for the competing risk of death, and using inverse-weighting by the probability of having creatinine measured in that time period were similar to the primary analysis ( Figure S4 ).
Mediation analysis
Mediation analysis suggested that the eGFR decline after surgery statistically explained much of the increased risk of ESRD after post-operative AKI. For example, 56%, 73%, and 61% of the risk associated with AKI Stage 1, Stage 2, and Stage 3 was accounted for by 30-day eGFR decline. These estimates were 62%, 76%, and 60%
at 60-days; 62%, 84%, and 67% at 90-days; and 75%, 83%, and 100% at 1-year. We note that while a decline in eGFR at a specified time point post-AKI is on the pathway from AKI to ESRD, it is not equivalent to ESRD, which is a severe and relatively rare event. In addition, ESRD has many causes apart from AKI, and which can include acute events that occur after an intermediate endpoint (e.g., medication toxicity, myocardial infarction). Thus, both sensitivity and positive predictive value are low, since eGFR decline within an early follow-up interval post-AKI is not necessary or sufficient to cause ESRD. This point is exemplified by the prediction statistics, which demonstrate some of the differences between a potentially useful surrogate and a perfect predictor. Although prediction statistics are informative, even widely accepted surrogates such as LDL cholesterol for myocardial infarction have low sensitivity and positive predictive value. 20 On the other hand, a low sensitivity may also hamper evaluation of treatment effects on ESRD in clinical trials.
DISCUSSION
Similar to recent work in CKD, our results suggest that a 30%-40% decline may be a surrogate for ESRD after in-hospital AKI. It also suggests that the most important aspect of AKI prevention may be lessening the risk of subsequent eGFR decline, or the irreversible loss of kidney function after an episode of AKI. When eGFR decline should be measured post-injury is uncertain, but associations were strong even at 30 days post-hospital discharge, and were stronger with confirmed eGFR decline as assessed by repeat measurement. The KDIGO guidelines recommend assessment at 90 days for ascertainment of development or progression of CKD after an episode of AKI. 21 Our data show that this later time point is associated with higher risk, possibly reflecting irreversible loss of kidney function, or that it is less affected by the competing risk of mortality, and providing stronger evidence of surrogacy. On the other hand, eGFR decline detected at later time points may be caused by intervening events post-hospitalization, unrelated to the AKI, and thus may be less preventable than eGFR decline at an earlier time point. Our results are consistent with previous work demonstrating worse outcomes among people who do not recover eGFR after an episode of AKI compared with those who do recover.
10,22-24
The current study focuses on post-operative AKI. Cardiac surgery is a common setting for clinical trials of AKI prevention. 25, 26 An advantage of the post-operative environment in clinical trials of AKI is that the timing of the insult may be well-defined, particularly for cardiac and vascular surgery, and thus interventions can be delivered at a specific time relative to the anticipated/observed insult. A second advantage of the post-operative environment as a setting for clinical trials is that surgery is usually avoided in persons at high risk of mortality.
Even the most effective therapy for AKI prevention may not prevent short-term mortality, given the availability of renal replacement therapy, and thus a higher frequency of mortality will reduce power for a given study design. Even in our study, the absolute risk of mortality far exceeded the risk of ESRD, as seen in the low positive predictive value; the use of a composite endpoint of ESRD and death would result in weaker associations. Relationships between eGFR decline after AKI and subsequent ESRD should be validated in alternative clinical settings commonly used in trials, such as post-cardiac catheterization or iodinated contrast administration.
In addition to providing a more plausible surrogate for progression to ESRD than an acute and transient change, The strengths of this study include its large, nationally-based study population, the rigorous quantification of eGFR decline and stages of AKI, and linkage to subsequent outcomes. Follow-up for ESRD and mortality is presumed to be complete given the linkage to reliable government sources. However, we relied on assessment of post-discharge eGFR as it was obtained in clinical care, and this ascertainment bias resulted in sicker patients selected into our cohort. However, sensitivity analyses weighting by the inverse probability of creatinine measurement demonstrated consistent results. Another limitation is that the VA population consists of mostly men, and veterans may be different from the general population in many other ways as well. We did not have complete information on baseline proteinuria and thus could not adjust for this important confounder. Comorbid conditions were determined by diagnostic code, which has uncertain and possible differential validity.
Medication use was captured by provider prescription and compliance was unknown. With all observational analysis, residual confounding is possible; mediation analysis is particularly susceptible. Our mediation analysis was only a secondary analysis but should be interpreted with caution. Finally, only 12% of the population had eGFR <60 ml/min/1.73 m 2 , which differs from many AKI clinical trial populations which are enriched for participants with kidney disease. Future studies should validate these associations in other settings and cohorts, including clinical trials, where treatment effects can be evaluated.
In conclusion, we present data from a large national cohort of veterans undergoing major surgery that demonstrate that a 30%-40% decline in eGFR post-discharge may be potential surrogate endpoint in clinical trials of AKI prevention. Unlike other clinical biomarkers, it is directly on the pathway from AKI to ESRD, and appears to largely explain the excess risk associated with AKI. Although this endpoint would be considerably more common than ESRD, a suitably-powered trial of AKI prevention may still require thousands of patients, and its use requires additional study of treatment effects in clinical trials. Future research is needed to determine whether other clinically meaningful endpoints such as length of stay or hospital readmission might also be useful in drug approval procedures.
CONCISE METHODS
Study population
The study population has been previously described. Warehouse LabChem data files were included in the initial data pull. For the present study, only patients undergoing major cardiac, thoracic, vascular, orthopedic, general, urologic, or ear/nose/throat surgery between cohort enrollment date and September 15, 2011 were included (N=310,894). 31 For these patients, the first qualifying surgery was used as the index hospitalization. We excluded patients with pre-hospitalization ESRD and those undergoing surgery more than 30 days after hospital admission, for a final study population of 161,185 participants. Because the surgery could occur any time during the follow-up period, many participants (12% of the study population) had developed eGFR <60 ml/min/1.73 m 2 prior to surgery.
Definitions of AKI and eGFR decline
Post-operative AKI was staged according to KDIGO creatinine-based criteria from the date of surgery, identifying AKI as an increase in serum creatinine from baseline of 0.3 mg/dL within 48 hours or 50% within 7 days. assessments of eGFR were made in a given time window, the mean eGFR was used. The magnitude of eGFR decline was assessed continuously and using complete case analysis. Given the strength of associations, we focused our discussion on 30-, 60-and 90-day time periods and 30% and 40% decline. In sensitivity analysis, we required two measurements of eGFR decline in the time window as a proxy for confirmation of decline.
Definitions of covariates and outcomes
Surgery type was determined from ICD-9-CM procedure codes in the VA Inpatient Medical Dataset and categorized according to the Clinical Classifications Software procedural classification system (Table S4) .
Laparoscopic surgery, hypertension, diabetes, coronary artery disease, congestive heart failure, peripheral arterial disease, cerebrovascular disease, liver disease, and lung disease were defined by a qualifying inpatient or outpatient ICD-9-CM code (Table S5) . 32, 33 Body mass index (BMI) was defined as the average outpatient value in the 7-365 days prior to admission using the VA Corporate Data Warehouse. Medication use (angiotensin converting enzyme inhibitor (ACE-I), angiotensin receptor blocker (ARB), diuretic, and statin) was determined by VA Pharmacy dispensation records in the 3 months prior to surgery. Outcomes included ESRD and mortality, as determined through linkage to the VA Vital Status Files and the US Renal Data System, respectively, with follow-up until 2011.
Statistical analysis
Survival to various time-points post-discharge was assessed using a Kaplan-Meier approach. Odds of eGFR decline associated with stage of AKI were determined using logistic regression. Cox proportional hazards regression was used to determine the association of eGFR decline with subsequent ESRD and mortality, with Figure 1 : Risk of ESRD associated with post-discharge change in eGFR after major surgery, by post-operative AKI status (upper half of graph); distribution of post-discharge change in eGFR after major surgery, by post-operative AKI status (lower half of graph); both estimates at 30-days (A), 60-days (B), 90-days (C), 180-days (D), and 365-days (E), post-discharge.
*Black diamond refers to stable eGFR among those without AKI, the reference. The red circle refers to an eGFR decline of 30% among those with AKI. The red line is at eGFR decline 30%, and the red percentage refers to the prevalence of eGFR decline ≥30% among those survivors with post-operative AKI. The y-axis is depicted on the log scale. Table S2 : Number of participants, ESRD events, and mortality events by category of eGFR decline and AKI stage . 3 Table S3 : Hazard ratios for all-cause mortality stable eGFR, 30% eGFR decline, and 40% eGFR decline after major surgery, by presence and *Black diamond refers to stable eGFR among those without AKI, the reference. The red circle refers to an eGFR decline of 30% among those with AKI. The red line is at eGFR decline 30%, and the red percentage refers to the prevalence of eGFR decline ≥30% among those survivors with post-operative AKI. participants by the inverse of their probability of having a creatinine measurement during the time window (C).
*Black diamond refers to stable eGFR among those without AKI, the reference. The red circle refers to an eGFR decline of 30% among those with AKI. 
